Gene · 57761
Papers2,228
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
61 to 80 of 2,228
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
Extending MET-TRIB3 axis research in hepatocellular carcinoma: Immune contexture and patient subgroups: Letter to the editor on "MET promotes hepatocellular carcinoma development through the promotion of TRIB3-mediated FOXO1 degradation". | Clin Mol Hepatol | 2026 | 41548579 | PubTator, text mining | PubMed |
| RAAS antagonists dampen the SARS-CoV-2 infection in ex-vivo cultured human precision-cut lung slices. | Respir Res | 2026 | 41530760 | PubTator, text mining | PubMed |
A prognostic model for human papillomavirus-negative head and neck squamous cell carcinoma based on a novel ferroptosis-related gene signature: Development, validation and elucidation of its relationship with the immune microenvironment. | Oncol Lett | 2026 | 41473698 | PubTator, text mining | PubMed |
| Letter to the editor 1 on "MET promotes hepatocellular carcinoma development through the promotion of TRIB3-mediated FOXO1 degradation". | Clin Mol Hepatol | 2026 | 40485098 | PubTator, text mining | PubMed |
| Letter to the editor 2 on "MET promotes hepatocellular carcinoma development through the promotion of TRIB3-mediated FOXO1 degradation". | Clin Mol Hepatol | 2026 | 40485097 | PubTator, text mining | PubMed |
| Reply to correspondence 2 on "MET promotes hepatocellular carcinoma development through the promotion of TRIB3-mediated FOXO1 degradation". | Clin Mol Hepatol | 2026 | 40462646 | PubTator, text mining | PubMed |
| Reply to correspondence 1 on "MET promotes hepatocellular carcinoma development through the promotion of TRIB3-mediated FOXO1 degradation". | Clin Mol Hepatol | 2026 | 40452228 | PubTator, text mining | PubMed |
Uncovering the MET-TRIB3-FOXO1 axis: A novel target in MET-driven hepatocellular carcinoma: Editorial on "MET promotes hepatocellular carcinoma development through the promotion of TRIB3-mediated FOXO1 degradation". | Clin Mol Hepatol | 2026 | 40369899 | PubTator, text mining | PubMed |
| Correspondence to Editorial 2 on "MET promotes hepatocellular carcinoma development through the promotion of TRIB3-mediated FOXO1 degradation". | Clin Mol Hepatol | 2026 | 40369897 | PubTator, text mining | PubMed |
| Correspondence to Editorial 1 on "MET promotes hepatocellular carcinoma development through the promotion of TRIB3-mediated FOXO1 degradation". | Clin Mol Hepatol | 2026 | 40356275 | PubTator, text mining | PubMed |
Unveiling TRIB3: A new mediator in MET-driven hepatocellular carcinoma progression: Editorial on "MET promotes hepatocellular carcinoma development through the promotion of TRIB3-mediated FOXO1 degradation". | Clin Mol Hepatol | 2026 | 40294893 | PubTator, text mining | PubMed |
| Decoding cellular stress states for toxicology using single-cell transcriptomics. | NAM J | 2025 | 42369397 | PubTator, text mining | PubMed |
| Integrating multi-omics data and machine learning to identify endocrine disrupting chemicals targeting key ccRCC-related genes. | Discov Oncol | 2025 | 41467947 | PubTator, text mining | PubMed |
| Post-onset intermittent fasting attenuates neuroinflammation and demyelination via a TRIB3-PERK-autophagy axis in an EAE model of multiple sclerosis. | J Neuroinflammation | 2025 | 41299682 | PubTator, text mining | PubMed |
| ELF4/TRIB3/CDK6 Axis Promotes Cancer Stem Cell Activity in Endometrial Cancer. | J Cell Physiol | 2025 | 41287970 | PubTator, text mining | PubMed |
| A Riskscore Model for Predicting Survival, Tumor Microenvironment, Immunotherapy and Drug Sensitivity of Lung Squamous Cell Carcinoma Based on PI3K/AKT/MTOR Pathway-Related Genes. | J Environ Pathol Toxicol Oncol | 2025 | 41213060 | PubTator, text mining | PubMed |
| Uncovering the Tumorigenic Blueprint of PFOS and PFOA Through Multi-Organ Transcriptomic Analysis of Biomarkers, Mechanisms, and Therapeutic Targets. | Curr Issues Mol Biol | 2025 | 41020885 | PubTator, text mining | PubMed |
| Omics characteristics and epigenetic modifications of adipose-derived stem cells. | J Biol Chem | 2025 | 41005477 | PubTator, text mining | PubMed |
| Integrative assessment of RNA sequencing and in silico analysis to pinpoint mRNAs, lncRNAs, and circRNAs interactions with miRNAs underlying arsenic-induced neurotoxicity. | BMC Genomics | 2025 | 40999364 | PubTator, text mining | PubMed |
| TRIB3 promotes endometrial cancer progression through interacting with E2F1 and enhancing PKM2-mediated tumor glycolysis. | Gynecol Oncol | 2025 | 40997650 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/57761/papers?page=4